BMJ Open

Protocol for the China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) Million Persons Project pilot

Jiapeng Lu,[1] Si Xuan,[2,3] Nicholas S Downing,[2] Chaoqun Wu,[1] Li Li,[1] Harlan M Krumholz,[2,3,4] Lixin Jiang[1]

To cite: Lu J, Xuan S, Downing NS, *et al*. Protocol for the China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) Million Persons Project pilot. *BMJ Open* 2016;**6**:e010200. doi:10.1136/bmjopen-2015-010200

► Prepublication history and additional material is available. To view please visit the journal (http://dx.doi.org/10.1136/bmjopen-2015-010200).

JL and SX are the co-first authors. HMK and LJ are joint senior authors.

Received 6 October 2015
Revised 10 November 2015
Accepted 26 November 2015

For numbered affiliations see end of article.

Correspondence to
Professor Lixin Jiang;
jiangl@fwoxford.org

ABSTRACT

Introduction: Collection of high-quality data from large populations is considered essential to generate knowledge that is critical to an era of precision medicine. Cardiovascular disease (CVD) is a leading cause of mortality in China and is a suitable focus of an initiative to discover factors that would improve our ability to assess and modify individual risk.

Methods and analysis: The pilot phase of China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) Million Persons Project is being conducted during 2014–2015 in four provinces across China to demonstrate the feasibility of a population-based assessment. It is designed to screen 0.4 million community-dwelling residents aged 40–75 years with measurements of blood pressure, height and weight, a lipid blood test, and a questionnaire on cardiovascular-related health status. Participants identified at high risk of CVD receive further health assessments, including ECG, ultrasound scan, blood and urine analysis, and a questionnaire on lifestyle and medical history. Collection of blood and urine samples is used to establish a biobank. High-risk subjects are also counselled with suggestions regarding potential lifestyle changes. In addition, high-risk subjects are followed-up either in a return clinic visit or by telephone interview, with measurement of blood pressure, weight, ECG, and a questionnaire on survival status, hospitalisations and lifestyle. The first 0.1 million participants screened were used to conduct a preliminary analysis, with information on baseline characteristics, health-related behaviours, anthropometric variables, medical history, and prevalence of high-risk subjects.

Ethics and dissemination: The central ethics committee at the China National Center for Cardiovascular Disease (NCCD) approved the pilot. Written informed consent is obtained from all participants on entry into the project. Findings will be disseminated in future peer-reviewed papers and will inform strategies aimed at developing precise methods of assessing and modifying risk.

Trial registration number: NCT02536456.

Strengths and limitations of this study

- The pilot is the first large-scale population-based screening project in China aimed at identifying subjects at high risk of cardiovascular disease (CVD) and collecting detailed information and biospecimens as part of a precision medicine project.
- With rigorous methodological design and data collection, this public health effort can serve as a powerful research-grade database for future precision medicine investigations into the biological, environmental, behavioural and other contextual factors associated with CVD in the Chinese population.
- The pilot project was conducted primarily to test the feasibility of a large-scale screening project, and the integrated quality assurance procedures ensure its ability to act as a reliable resource for future research.
- Insights garnered from this project will inform approaches for future efforts in developing individualised approaches to primary and secondary CVD prevention in China.

INTRODUCTION

A central challenge in medicine is to individualise approaches to patient treatment. However, much of medicine is based on study results of averages for populations, and there is a general lack of knowledge about how best to individualise strategies. Precision medicine is a term that refers to efforts to better understand individual differences and to tailor clinical care for each person in a more customised way.[1] To generate knowledge about individuals requires studies of massive numbers of people, so that those with similar characteristics can be studied and their risks understood.

China is an ideal country to undertake such studies because of its large population, and cardiovascular disease (CVD), a major

public health challenge in China, is a suitable condition for the focus of such an initiative. Few Chinese adults have ideal cardiovascular health,[2] and the increasing prevalence of hypertension,[3] diabetes,[4] smoking[5] and obesity,[6] combined with an aging population,[7] is likely to result in increasing numbers of CVD events in the years to come. For example, it is predicted that CVD events in China will increase by more than one half of their current value over the next two decades,[8] and that there could be as many as 20 million myocardial infarctions (MIs) and 30 million strokes per year by 2030.[9]

Risk factor modification has the potential to prevent CVD and is broadly recommended by international guidelines for the prevention of CVD.[10 11] Evidence from randomised controlled trials has shown that lipid-lowering treatments using statin[12–15] and antihypertensive drugs[16 17] may reduce the incidence and mortality rates of CVD. In addition to changes in medication, lifestyle interventions such as smoking cessation,[18] increased physical activity[19 20] and dietary improvements[21–23] are also associated with lower rates of incidence of CVD. However, the value of preventive interventions depends on an individual's cardiovascular risk.[24–26] Therefore, efficient identification of those at high CVD risk is necessary for the proper implementation of disease-prevention strategies.

Unfortunately, many patients in China have CVD risk factors that remain undiagnosed and uncontrolled. For example, a cross-sectional national survey of Chinese adults estimated that 70% of diabetes cases were undiagnosed, and even those that were diagnosed were commonly not well controlled, especially in underdeveloped regions.[27] This pattern was also common in cases of dyslipidaemia and hypertension.[28 29] To date, there has been no large-scale, population-based screening study implemented in China to identify and counsel subjects with high CVD risk. Knowledge regarding Chinese adults with high CVD risk is also limited; very few studies have recognised high-risk rural patients.[30]

Consequently, the Chinese government has committed to the China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) Million Persons Project (MPP), the pilot protocol of which we report here. China PEACE is an administrative structure to support the generation and implementation of studies to improve the care and outcomes of patients in China—and produce knowledge that will help people around the world. China PEACE MPP is a population-centred national screening initiative to detect populations at high risk of CVD. It will collect biospecimens and detailed information on sociodemographics, disease histories, extreme phenotypes, lifestyles, and behaviours for millions of people. Previously published China PEACE studies have focused primarily on care and outcomes for patients who have had acute MI and/or percutaneous coronary intervention (PCI).[31 32] Moving beyond such hospital-based studies, China PEACE MPP will add knowledge about broader population-based cardiovascular health and generate important insights into primary and secondary prevention of CVD in China. Our work is similar in nature to the Precision Medicine Initiative (PMI) launched in the USA in January 2015, which aims to recruit 1 million Americans and 'will encourage and support the next generation of scientists to develop creative new approaches for detecting, measuring, and analysing a wide range of biomedical information—including molecular, genomic, cellular, clinical, behavioural, physiological, and environmental parameters.'[33] Like the PMI, our national screening initiative will collect biological samples and lifestyle information from a voluntary national research cohort to create a platform for precision medicine studies. Using collected information, researchers will be able to investigate individual differences in genes, behaviours and lifestyles to advance the emerging field of precision medicine. The US PMI will put a near-term focus on supporting more and better cancer treatments, whereas our study will focus on cardiovascular health. Further investigation of cardiovascular health is especially important in a country such as China, which has an aging population and is increasingly urbanised. Our initiative should, in the long run, provide important insights in informing future efforts to develop more individualised approaches to CVD prevention and intervention. In the near-term, the public health component of this initiative seeks to address the nation's pressing needs to identify high-risk CVD subjects, characterise population risk factors, and define the relationship between risk factors and CVD outcomes in high-risk populations.

This effort, funded by the Ministry of Finance (MOF) of China and the National Health and Family Planning Commission (NHFPC) of China, was initially planned for 0.4 million people across four provinces, with the potential for expansion to 4 million across the country. Thus, the China PEACE MPP Pilot is designed to determine if a much-needed and large-scale public health effort could be feasibly paired with a high-quality research programme to amass a database capable of supporting and advancing precision medicine research in China. The pilot launched in 2014 is using methodologies that include a rigorous protocol design, standardised operational features, data collection methods capable of promoting future investigation, and the establishment of a biobank. The goal of the pilot is to determine the feasibility of a subsequent future nationwide screening project and will also generate data for future research on the understanding and prevention of CVD.

METHODS

Design overview

The pilot of the China PEACE-MPP began in July 2014 and has continued into 2015. The pilot project is taking place in four provinces, which were chosen according to their local available human resources and capacity to perform a large-scale screen. About 0.4 million residents

are being screened using measurements of blood pressure, height and weight, a lipid blood test, and a questionnaire assessing cardiovascular-related health status. This process aims to identify subjects with high CVD risk, where 'high CVD risk' is defined as meeting one of the following criteria: (1) history of established CVD; (2) high blood pressure; (3) dyslipidaemia; (4) a 10-year risk of CVD ≥20%.[34] These high-risk subjects then receive a detailed assessment of their cardiovascular health based on information collected from an ECG, ultrasound scans, biosampling, laboratory tests, and an extended questionnaire assessing lifestyle (eg, smoking, physical activity, diet) and medical history. In addition, the high-risk subjects are counselled with suggestions regarding potential lifestyle changes (eg, smoking cessation, increasing physical activity, weight loss). High-risk subjects are followed-up either in a return clinic visit or through a telephone interview. In the pilot, we conducted a 1-month follow-up to test if a high rate for such a large-scale follow-up could be achieved. The follow-up assessment consists of blood pressure and weight measurements, an ECG, and a questionnaire assessing cardiovascular health status.

The central ethics committee at the China National Center for Cardiovascular Disease (NCCD) approved the pilot. The Chinese government, which provides financial support, has had no role in the design or administration of the study, the collection, management, analysis or interpretation of the data, or the preparation or approval of this paper. Written informed consent is obtained from all participants on entry into the project. The informed consent form states that all personal information and any results from the physical measurements, laboratory tests and other tests are confidential and stored in an encrypted database. Knowledge generated from this project will be disseminated in future peer-reviewed papers and will inform strategies aimed at developing precise prevention and intervention methods for CVD.

Pilot sites and recruitment

The pilot is conducted in 20 geographically defined regions (11 urban districts and 9 rural counties) of four provinces (Jilin, Liaoning, Zhejiang and Guangxi) in China (figure 1). The regions were selected on the basis of their geographic location, quality of disease and death registries, and local capacity to support the pilot. In each region, 3–5 urban residential communities or rural villages were chosen according to community or village size, population stability (eg, no sudden significant change in the number of residents), and commitment and ability of local workers to perform the screening. Initial screening stations were set up in each community or village health centre. Subjects identified as being at high risk of CVD at a screening station are then moved to a designated hospital within each region to receive further assessment, counselling and follow-up care. Each hospital is selected on the basis of its distance from local residents and its ability to perform laboratory tests, ECGs, ultrasound scans and health counselling.

Potentially eligible participants are identified in each community or village through official residential records, and then invited by local community workers via extensive publicity campaigns on the television and in the newspapers. The participant response rate for each community or village will be related to its known populations. All participants are required to bring their identity cards to the screening centre to verify that they meet both of the inclusion criteria: (1) aged 40–75; (2) registered in the Hukou (a record officially identifying a person as a resident of an area) of the selected region. The qualifying age range of 40–75 years was chosen according to the WHO/International Society of Hypertension (ISH) cardiovascular risk prediction charts.[34] After verification of residency, participants who have signed the informed consent agreement (see online supplementary appendix 1) are then enrolled for initial screening.

Initial screening protocol

Participants are first asked for sociodemographic information (eg, education, income, health insurance; see online supplementary appendix 2). They then receive a physical examination, a lipid blood test and an in-person interview performed by trained medical staff. The whole screening process takes about 30 min to complete.

Physical measurements

For each participant, blood pressure is measured on the right upper arm after 5 min of rest in a seated position using an electronic blood pressure monitor (Omron HEM-7430; Omron Corporation, Kyoto, Japan). Blood pressure is measured twice, with 1 min between the measurements. The two readings are then recorded and their mean value is calculated in order to identify people at high CVD risk. If the difference between the two systolic blood pressure (SBP) readings is larger than 10 mmHg, a third blood pressure measurement is taken, and the mean value of the last two readings is calculated. Heart rate readings are also collected using the electronic blood pressure monitor. Participants are required to wear light clothes, no shoes and no cap when trained technicians measure their height and weight. Weight is measured to the nearest 0.1 kg, and height is measured to the nearest 0.1 cm. Body mass index (BMI) is calculated by dividing weight in kilograms by height in metres squared.

Lipid blood test

A non-fasting lipid blood test that measures total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) is performed by a rapid lipid analyser using fingertip blood samples (CardioChek PA Analyzer; Polymer Technology Systems, Indianapolis, Indiana, USA). This device uses reflected light to measure an

Figure 1 Geographic distribution of pilot sites. The pilot sites are located in 20 geographically defined regions from four provinces (Jilin, Liaoning, Zhejiang, Guangxi) in China. The 20 local regions consist of 11 urban districts and 9 rural counties.

end point enzymatic chemical reaction. The lipid panel test strips are designed for testing of TC, TG and HDL-C. LDL-C is calculated using the values of TC, HDL-C and TG levels in the Friedewald equation. A daily quality control check of the device is performed using the grey check strip test, which verifies the accuracy of the device's electronic and optical systems.

Initial questionnaire on cardiovascular health status

After the physical measurements and lipid blood test are completed, participants have a 5–10 min in-person interview with a trained staff member using a computer-delivered questionnaire (see online supplementary appendix 3). In order to identify high-risk subjects, the questionnaire assesses: cigarette smoking status; alcohol consumption; self-reported history of hypertension, diabetes, MI, PCI, coronary artery bypass grafting (CABG), and stroke; self-reported history of medication; and extreme phenotypes (as indicated by family history of longevity, premature death and prevalent chronic diseases). Participants are classified as current smokers if they answer, 'Yes' to the question, 'Do you currently smoke cigarettes?' A full list of variables is given in table 1.

A written health report including the results of the physical measurements and the lipid blood test is given to each initial screening participant (see online supplementary appendix 4).

Identification of high-risk subjects

Participants are considered at high risk of CVD if they meet at least one of four criteria (figure 2). The criteria are adapted from WHO guidelines for the assessment and management of cardiovascular risk.[34] In recognition of the lower lipid levels found in the Chinese population, the WHO lipid criteria were adjusted so that more individuals could be classified as high-risk subjects and the relationship between more modestly elevated lipid levels and CVD risk could be determined. The four criteria for eligibility for the pilot are:

1. History of at least one of the following cardiovascular events
   MI, PCI, CABG treatment, or stroke (either ischaemic or haemorrhage)
2. High blood pressure
   Defined as SBP≥160 mmHg or diastolic blood pressure (DBP)≥100 mmHg
3. Dyslipidaemia
   Defined as LDL-C≥160 mg/dL (4.14 mmol/L) or HDL-C<30 mg/dL (0.78 mmol/L)
4. Risk of CVD in 10 years ≥20% based on WHO/ISH Cardiovascular Risk Prediction Charts for the Western Pacific Region B[35]
   Risk is determined using the following information: age, gender, smoking status, presence or absence of diabetes, SBP and TC. The risk of CVD is calculated by a predetermined algorithm derived

Table 1 Information collected in the pilot project

Domain	Initial screening	Assessment for high-risk subjects	1-month follow-up
Patient interviews			
Health behaviours			
Smoking	√	√	√
Alcohol use/misuse	√	√	√
Physical activity		√	√
Dietary		√	√
Medical history			
Hypertension	√		
Diabetes	√		
MI	√		
PCI	√		
CABG	√		
Stroke	√		
Angina		√	
Heart failure		√	
Valvular heart disease		√	
Arrhythmia		√	
Hypercholesterolaemia		√	
Dyslipidaemia		√	
Chronic renal disease		√	
Peripheral vascular disease		√	
Cancer (except skin cancer)		√	
Family history of disease			
Hypertension		√	
CHD		√	
Ischaemic stroke		√	
Haemorrhage stroke		√	
Diabetes		√	
Cancer		√	
Hypercholesterolaemia		√	
Identification of special case			
Family history of longevity, premature death, and chronic disease	√		
Medication history			
Antihypertension	√		
Lipid-lowering	√		
Antidiabetic	√		
Antiplatelet	√		
Traditional Chinese medicine	√		
Menstruation			
Menstrual period		√	
Menopause		√	
Pregnancy		√	
Quality of life (EQ-5D-3L)		√	√
Survival status			
Date and cause of death			√
Hospitalisations			
Date of admission			√
Length of hospitalisation			√
Diagnosis of discharge			√
Physical measurements			
Blood pressure	√		√
Height	√		
Weight	√		√
BMI	√		
Lipid blood test	√		
TC	√		

Continued

Table 1 Continued

Domain	Initial screening	Assessment for high-risk subjects	1-month follow-up
TG	√		
LDL-C	√		
HDL-C	√		
Imaging examinations			
ECG		√	√
Echocardiogram		√	
Carotid artery ultrasound		√	
Biosamples			
Blood		√	
Urine		√	
Laboratory analysis			
Biochemistry test			
Blood lipid		√	
Glucose		√	
ALT		√	
AST		√	
Creatinine		√	
Uric acid		√	
HbA1c		√	
Urine routine test			
Glucose		√	
Ketone		√	
Occult blood		√	
Protein		√	
Nitrite		√	
Bilirubin		√	
Gravity		√	
pH		√	
Urobilinogen		√	
Erythrocyte		√	
Leucocyte		√	

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CABG, coronary artery bypass grafting; CHD, coronary heart disease; ECG, 12-lead ECG; HbA1c, glycated haemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; PCI, percutaneous coronary intervention; TC, total cholesterol; TG, triglyceride.

from the WHO/ISH cardiovascular risk prediction charts for the Western Pacific Region B.[35] Individuals with ≥20% risk of CVD are considered to be high-risk subjects.[34]

Health assessment of high-risk subjects

Following their initial screening, all high-risk subjects receive a detailed assessment of their cardiovascular health based on physical measurements, biosamples, laboratory tests and an extended questionnaire.

Physical measurements

Trained medical staff members from local hospitals perform a 12-lead ECG using a multichannel ECG machine linked to an ECG interpretation and transfer computer system (HW-E100; Hanwei Medical Group, Hebei, China). Local ultrasound physicians then conduct echocardiography and a carotid artery ultrasound scan in accordance with standards set down by the NHFPC, China. Trained ultrasound physicians interpret and provide the written results of the echocardiogram and the carotid artery ultrasound scan to high-risk subjects (see online supplementary appendices 5 and 6). The quality control team, which consists of the senior ultrasound physicians from that local site, monitors medical staff compliance with ultrasound protocols on a daily basis. Every day, they randomly select 5% of all ultrasound images to determine whether any data entry errors have occurred. Echocardiography and carotid artery ultrasound images are stored at local sites and transmitted on a monthly basis to the NCCD using an encrypted hard disk in Digital Imaging and Communications in Medicine (DICOM) format.[36] For some rural hospitals that cannot provide DICOM files, static images are stored in JPG format, and dynamic images are stored in a video format such as AVI. Trained ultrasound physicians from the NCCD verify the results of the ECGs and ultrasound scans once those images have been transmitted to the NCCD.



Figure 2 Criteria for identification of high-risk subjects.

Biosamples

For each high-risk patient, a 5 or 6 mL whole blood sample is collected in an EDTA vacuum tube in order to test for haemoglobin A1c (HbA1C). A second 5 or 6 mL whole blood sample is drawn into a serum gel tube for analysis of the biochemical values of the serum. A 10 mL urine sample is also collected. Within 24 h of collection, the blood samples are divided into aliquots and centrifuged at 2100 *g* for 10 min. The plasma, serum and urine samples are then pipetted into 2 mL cryovials. All filled cryovials and EDTA vacuum tubes are immediately stored at −40°C or −80°C, then transported to the NCCD within 1 month and stored at −80°C or −180°C for central calibration analysis and long-term storage.

Laboratory tests

A 1 mL sample of serum is used to perform a biochemistry test measuring blood lipid, glucose, alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine and uric acid levels. The HbA1c value is determined via the ionic-exchange high-performance liquid chromatography method (VARIANT II Haemoglobin Testing System; Bio-Rad Laboratories, Hercules, California, USA). In addition, the urine sample is used to conduct a urine routine test measuring glucose, ketone, occult blood, protein, bilirubin and leucocyte levels.

Extended questionnaire on cardiovascular health status

After the physical measurements and laboratory tests, high-risk subjects take part in an extended in-person interview. The interviewer-administered questionnaire includes the following eight topics (see online supplementary appendix 7): smoking (eg, frequency, tobacco type);[37] alcohol use/misuse (eg, frequency, dependence symptoms; assessed using the Alcohol Use Disorders Identification Tool (AUDIT));[38] physical activity (eg, activities available in urban or rural locations, exercise level in leisure time);[37] diet (eg, frequency of rice, meat, or vegetable consumption);[37] personal medical history; family medical history; menstruation and pregnancy history;[39] and quality of life (assessed using the EQ-5D-3L[40]). Questions were adapted from prior population-based epidemiological studies in China.[37 41] The validity and reliability of AUDIT and EQ-5D-3L applied to the Chinese population have been previously evaluated.[38 40] A full list of variables is shown in table 1.

A written report on the results of the further assessment of high-risk subjects is given to each participant (see online supplementary appendix 8).

Counselling for high-risk subjects

After the in-person interview, high-risk subjects are advised with general recommendations for healthy lifestyle changes by trained cardiologists. The counselling includes the following eight general recommendations,

given as needed to patients based on their in-person interview results: stick to a healthy, low-fat diet; engage in regular physical activity; lose weight; quit smoking; limit alcohol consumption; maintain a healthy daily routine with sufficient sleep; have a routine annual physical examination (eg, blood pressure, heart rate); and comply with all medication requirements. In addition, potential CVD patients are recommended to obtain further diagnoses and treatments. A list of the recommendations is included in online supplementary appendix 8.

After counselling, all high-risk subjects are asked to set up a 1-month follow-up appointment.

Follow-up of high-risk subjects

To track changes in their lifestyles and risk factor statuses, high-risk subjects are followed-up after 1 month, either in a return clinic visit or by telephone interview. A return clinic visit includes physical measurements and a face-to-face interview. The physical measurements include blood pressure, weight, and an ECG using the same standard protocols applied in the screening phase. Results of the follow-up examination are recorded in a report (see online supplementary appendix 9). The face-to-face interview is administered by a trained interviewer to investigate the subject's survival status, hospitalisations, health-related lifestyle status (eg, smoking, alcohol use/misuse, physical activity, diet),[37 38] and quality of life[40] (see online supplementary appendix 10). Telephone interviews are offered to any subjects who are unable to make a return clinic visit. A full list of variables examined is included in table 1.

A written report on the results of the follow-up of high-risk subjects is given to each participant (see online supplementary appendix 9).

Data management

Data handling and quality control

Trained medical staff members enter all data from the questionnaires and health check-ups at each site into an off-line electronic data collection (EDC) system developed specifically for the pilot. To ensure the reliability and validity of the data, the off-line EDC system performs internal data checks to verify that the data being entered are complete and meet predefined data ranges and formats (see online supplementary appendix 11). The system displays a message warning users to correct or review data if they deviate from the predetermined data-checking rules. In addition, for each participant, the physical measurement data from the initial screening are entered into the off-line EDC system twice so that the system can verify their consistency.

At local sites, the data collected in the off-line EDC system are transferred to a central computer with internet access using an encrypted hard disk. Once transferred to the central computer, the data are then encrypted and confidentially stored in the NCCD.

A web-based project management platform was developed to monitor project progress and data quality. This platform also provides management support for the hospitals, staff members, equipment, sampling materials and funds used in the pilot.

Data security and confidentiality

All data, including health assessment results and questionnaires, are treated as protected information and are securely stored in an encrypted and password-protected database in the NCCD. This database can be accessed by only a limited number of approved staff members. At the local sites, all medical staff members must use their own passwords to log into the off-line EDC system. The passwords are used not only to ensure data security, but also to create an audit trail of all data entered or changed.

The data confidentiality policies (see online supplementary appendix 12) of the NCCD on data collection, storage and analysis have been strictly enforced in order to ensure the confidentiality of all personal information. The usage of the data is governed by the Research Guidance Committee, which consists of investigators from the NCCD and has been approved by an institutional review board.

Quality assurance

All local site medical staff members are trained in conducting blood pressure measurements, lipid blood tests, blood collection and sample processing, ECGs, ultrasound scans, face-to-face interviews and data entry. The local bureaus of quality and technical monitoring annually calibrate the site's electronic blood pressure monitor and rapid lipid analyser. In addition to the off-line EDC system's internal data-checking function, the validity of the collected data is verified monthly by searching for outliers in continuous data distributions, data with invalid and illogical values, and duplicate record entries. Once a potential error is found, data managers from the NCCD review the relevant records and resolve the problems (eg, correct invalid records, improve the data entry process, retrain local medical staff). When the data are being cleaned, outliers of measurement variables beyond the range of mean±3 times SD are removed.

In addition, on-site monitoring by trained staff members from the NCCD is conducted at least once at each local site during the pilot. The monitoring examines each site's documentation completeness and staff compliance with recruitment, screening, physical measurements, sample collection and processing protocols.

PRELIMINARY ANALYSIS

As the pilot is still in progress, we used the first 0.1 million subjects screened (25 000 in each province) to conduct preliminary data analysis. The current response rate of the initial screening participants was calculated using official residential records provided by each region. The mean values, prevalence rates, and SDs of the participants'

Table 2 Characteristics of screened subjects

	Male (N=42 469)		Female (N=57 531)		Total (N=100 000)		
	N or mean	% or SD	N or mean	% or SD	N or mean	% or SD	p Value*
Age (years)							<0.001
40–49	10 454	24.62	14 594	25.37	25 048	25.05	
50–59	13 651	32.14	19 536	33.96	33 187	33.19	
60–69	13 993	32.95	18 326	31.85	32 319	32.32	
70–75	4256	10.02	4979	8.65	9235	9.24	
Total†	57.06	9.27	56.59	10.68	56.79	10.11	<0.001
Han nationality	34 838	82.03	46 493	80.81	81 331	81.33	<0.001
Hukou status							<0.001
Non-agricultural	12 661	29.81	18 652	32.42	31 313	31.31	
Agricultural	21 716	51.13	29 109	50.60	50 825	50.83	
Unified Residency Hukou	8088	19.04	9765	16.97	17 853	17.85	
Do not have Hukou	4	0.01	5	0.01	9	0.01	
Marital status							<0.001
Married with spouse	40 543	95.46	52 244	90.81	92 787	92.79	
Widowed, separated, divorced	1379	3.25	4880	8.48	6259	6.26	
Never married	311	0.73	68	0.12	379	0.38	
Unknown	173	0.41	256	0.44	429	0.43	
Refuse to answer	63	0.15	83	0.14	146	0.15	
Education							<0.001
Illiterate	1283	3.02	4195	7.29	5478	5.48	
Less than primary school	1201	2.83	2590	4.50	3791	3.79	
Primary school	12 837	30.23	18 902	32.86	31 739	31.74	
Middle school	14 757	34.75	18 310	31.83	33 067	33.07	
High school	8508	20.03	9689	16.84	18 197	18.20	
College or university	3736	8.80	3681	6.40	7417	7.42	
Household income (Yuan/year)							<0.001
<5000	5426	12.78	7996	13.90	13 422	13.42	
5000–9999	2659	6.26	3888	6.76	6547	6.55	
10 000–19 999	7078	16.67	11 418	19.85	18 496	18.50	
20 000–50 000	15 646	36.84	19 369	33.67	35 015	35.02	
>50 000	5352	12.60	6260	10.88	11 612	11.61	
Unknown	1271	2.99	2198	3.82	3469	3.47	
Refuse to answer	5037	11.86	6402	11.13	11 439	11.44	
Current smoker	16 921	39.84	1503	2.61	18 424	18.42	<0.001
Alcohol drinker							<0.001
Never	22 148	52.15	51 703	89.87	73 851	73.85	
Monthly or less	3194	7.52	2293	3.99	5487	5.49	
2–4 times a month	5453	12.84	1487	2.58	6940	6.94	
2–3 times a week	11 337	26.69	1405	2.44	12 742	12.74	

All values are n (%) except for Total† which is mean (SD).
*χ^2 test for proportion and two-tailed t test (or t′ test if equal variances not assumed) for means, α=0.05.

baseline characteristics were calculated using χ^2 tests for comparison between men and women. The prevalence rates of high-risk subjects were also calculated using χ^2 tests for comparison among the four provinces. Preliminary data cleaning was conducted in order to remove missing values and outliers from the dataset. Data analysis was performed using the SPSS V.18.0 software package.

RESULTS

Demographic characteristics of participants

Of the 0.1 million participants aged 40–75 years in the present analysis, the estimated response rate was 32.1% for the three provinces (Liaoning, Jilin and Zhejiang) that have completed the initial screening. The follow-up rate was 74.3%. The demographic characteristics of the participants are shown in table 2. Among the 0.1 million participants, 42.5% were men, 50.8% were registered in the agricultural Hukou, and the mean±SD age was 56.8 ±10.1 years. Nearly all participants were married, and the proportion without a spouse (widowed, separated or divorced) was more than twice as high for women as for men (8.5% vs 3.3%). About half of the participants had at least 9 years of formal education. The prevalence of current smokers was significantly higher among men than women (39.8% vs 2.6%, p<0.001). The majority of participants reported that they had never drunk alcohol.

A significant difference in prevalence of regular alcohol drinkers was observed between men and women (26.7% vs 2.4%, p<0.001).

Baseline anthropometric parameters and medical history of the participants

Table 3 shows the anthropometric parameters and medical history of the first 0.1 million participants screened with valid baseline data. The mean BMI was 24.3 kg/m^2, with 37.8% qualifying as overweight or obese (≥25 kg/m^2). The prevalence of hypertension (SBP≥140 mm Hg or DBP≥90 mm Hg) was 47.6% in men and 43.9% in women. The proportion of participants reporting a history of hypertension was 20.9%, which was higher than that of any other chronic disease, and the proportion of those reporting hypertension was significantly higher among women than men (21.9% vs 19.4%, p<0.001). The proportion of participants who reported having a history of diabetes was 5.2% in men and 6.2% in women.

Prevalence of subjects with high CVD risk

The prevalence rates in each province of subjects with high CVD risk is shown in table 4. Overall, 26.9% of participants were identified as high-risk subjects. The proportion varied significantly between the four provinces, ranging from 21.1% to 35.8% (p<0.001). Of all the identified high-risk subjects, 20.8% had a prior history of CVD, 68.1% had high blood pressure, 25.3% had dyslipidaemia, and 26.1% had a 10-year CVD risk ≥20%. Again, each of these proportions varied significantly by area (p<0.001).

DISCUSSION

This pilot project is the first large-scale population-based screening initiative in China aimed at identifying subjects at high risk of CVD and collecting detailed information and biospecimens as part of a precision medicine project. Implemented using a rigorous methodological design and standardised health data collection methods, this public health effort may serve a variety of important purposes. First, it can make a tangible contribution to population health through its screening and intervention function. Second, it can be used as a research-grade database for future precision medicine investigation of population risk factors and outcomes of CVD. In addition, the pilot will expand current knowledge regarding China's growing epidemic of high-risk CVD, which will prove invaluable as China continues its epidemiological transition to a nation

Table 3 Anthropometric variables and medical history of screened subjects

	Male (N=42 469)		Female (N=57 531)		Total (N=10 000)		
Variable	N or mean	% or SD	N or mean	% or SD	N or mean	% or SD	p Value*
Height (cm)	166.81	6.91	156.22	6.42	160.72	8.45	<0.001
Weight (kg)	68.22	10.34	59.21	9.39	63.03	10.77	<0.001
BMI (kg/m^2)	24.46	3.05	24.23	3.36	24.33	3.24	
<18.5	583	1.37%	1449	2.52%	2032	2.03%	
18.5–24.9	25 237	59.42%	34 903	60.67%	60 140	60.14%	
25.0–29.9	14 656	34.51%	17 984	31.26%	32 640	32.64%	
≥30.0	1974	4.65%	3195	5.55%	5169	5.17%	
SBP (mm Hg)	140.53	19.33	138.96	20.54	139.63	20.05	<0.001
DBP (mm Hg)	82.91	10.78	80.10	10.80	81.29	10.88	<0.001
High blood pressure†	20 193	47.55%	25 275	43.93%	45 468	45.47%	<0.001
TC (mmol/L)	4.65	1.02	5.01	1.12	4.86	1.09	<0.001
TG (mmol/L)	1.88	1.17	2.02	1.19	1.96	1.18	<0.001
HDL-C (mmol/L)	1.44	0.46	1.58	0.45	1.52	0.46	<0.001
LDL-C (mmol/L)	2.50	0.84	2.65	0.90	2.58	0.88	<0.001
Medical history							
Hypertension	8254	19.44%	12 602	21.90%	20 856	20.86%	<0.001
Diabetes	2197	5.17%	3536	6.15%	5733	5.73%	<0.001
MI	512	1.21%	486	0.84%	998	1.00%	<0.001
PCI	272	0.64%	143	0.25%	415	0.42%	<0.001
CABG	39	0.09%	31	0.05%	70	0.07%	0.025
Stroke	2031	4.78%	2466	4.29%	4497	4.50%	<0.001
Haemorrhage stroke	1604	3.78%	2016	3.50%	3620	3.62%	
Ischaemic stroke	194	0.46%	161	0.28%	355	0.36%	

Values are n (%) or mean (SD) as indicated.
*χ^2 test for proportion and two-tailed t test (or t′ test if equal variances not assumed) for means, α=0.05.
†High blood pressure: SBP≥140 mmHg or DBP≥90 mmHg.
BMI, body mass index; CABG, coronary artery bypass grafting; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride.

Table 4 Prevalence of high-risk subjects of all and each type of high-risk criterion

Criterion	Liaoning N	Liaoning Per cent	Jilin N	Jilin Per cent	Zhejiang N	Zhejiang Per cent	Guangxi N	Guangxi Per cent	Total N	Total Per cent	p Value
Total CVD high-risk subjects	6712	26.85	8961	35.84	5269	21.08	5957	23.83	26 899	26.90	<0.001
CVD disease	1225	18.25	3061	34.16	347	6.59	968	16.25	5601	20.82	<0.001
High blood pressure	4898	72.97	5774	64.43	4156	78.88	3481	58.44	18 309	68.07	<0.001
Dyslipidaemia	1569	23.38	1857	20.72	1045	19.83	2340	39.28	6811	25.32	<0.001
WHO risk ≥20%	1817	27.07	2125	23.71	1450	27.52	1614	27.09	7006	26.05	<0.001
No risk	18 288	73.15	16 039	64.16	19 731	78.92	19 043	76.17	73 101	73.10	

χ^2 tests for proportion, α=0.05.
CVD, cardiovascular disease.

marked by a widespread rise in non-communicable diseases.

To counteract the expected upswing of CVD events in China in the years to come, national CVD prevention and intervention initiatives are urgently needed. This pilot is a novel, large-scale, longitudinal project on the modern Chinese epidemic of CVD. The project is designed to address the nation's knowledge gap regarding CVD and better inform future efforts in CVD prevention.

Previous large-scale, Chinese-population-based CVD studies have been limited to determining the prevalence of CVD risk factors without actually identifying high-risk subjects and comprehensively assessing their cardiovascular health.[37 39 42 43] Only one CVD study has identified a high-risk CVD population, but this study was hindered by the fact that it was cross-sectional and limited to rural residents in only one province.[30] Therefore, outside of this pilot project, there have been no other longitudinal, large-scale studies that use risk stratification to detect high-risk populations in China, and then conduct detailed health assessments and follow-up on them. In addition to its large scale, our pilot employed standardised, efficient and self-monitoring EDC on a wide range of information relevant to cardiovascular health and other disease, involved the mass storage of biospecimens, and included large-scale follow-up using clinical trial methodology. Thus, our pilot is unique in its ability to provide original and accurate data for characterising populations with high CVD risk through a highly efficient process. It is designed to answer research questions related to sociodemographics, biology, health behaviours, health trajectories, and the relationship between CVD risk factors and outcomes in high-risk populations. It will allow policymakers and academics to produce evidence-based research to inform future approaches to CVD prevention and intervention and may serve as a possible model for the development of similar projects in other countries.

In addition to informing future primary and secondary CVD prevention programmes, this pilot project has a wide range of public health implications. The data collected from the pilot could contribute to the establishment of a biobank aimed at promoting basic research that could provide essential knowledge regarding CVDs and other conditions. The pilot's wide range of data on biology, health behaviours and sociodemographics will serve as a powerful database for future investigators of CVD interested in topics, such as the complex interaction between a patient's lifestyle and genetic factors, that can act as a determinant of CVD. The pilot is also relevant to precision medicine, as it will allow better understanding of the genetic and non-genetic causes of CVD across a variety of conditions. In addition, the potential uses of the pilot extend beyond CVD. The biosamples and health behaviour data collected in the pilot may be applied to the study of effects of certain risk factors (eg, smoking, blood pressure, cholesterol) on other diseases. Lastly, the health assessment and data collection methodologies developed in the pilot have the potential to inform future strategies for the prevention and management of other non-communicable diseases.

The pilot will ultimately be implemented as a nationwide CVD screening project between 2015 and 2020, and may serve as a model for the development of similar projects in other countries. In the next phases, random sampling methods will be applied, and biosamples will be collected at the initial screening, which may promote future establishment of a biobank for millions of people in China. Considering the rising incidence of CVD in younger persons, we also plan to expand the current age range to 35–75 years. In addition, a long-term (1-year) follow-up of the pilot's high-risk subjects will be conducted later this year to collect important insights into the optimal development methods of a sustainable CVD prevention and intervention project. The follow-up will focus on several areas, including the efficacy of long-term behavioural health monitoring and risk factor modification.

Along with the rapid economic growth, urbanisation and westernised lifestyle, the prevalence of obesity, diabetes and hypertension in China has been dramatically

expanding. Our preliminary results showed that the prevalence of subjects with high CVD risk was 26.9%. According to the results, the prevalence of overweight, obesity and hypertension all increased significantly from their respective values reported in the 2002 China National Nutrition and Health Survey.[44 45] However, our data's estimated prevalence of current smokers has decreased from that reported in the 1996 National Prevalence Survey.[46] The proportion of subjects who reported having a history of diabetes remained similar to the results from the International Collaborative Study of Cardiovascular Disease in Asia (InterAsia).[43] Our results for blood pressure measurements and the combined prevalence of overweight and obesity were similar to those found in the China Kadoorie Biobank Study of 0.5 million people.[37] However, previous population-based studies conducted in China tended to include younger subjects than our sample. Compared with American adults, the combined prevalence of overweight and obesity based on our data was much lower in Chinese,[47] but the prevalence of hypertension was almost twice as high in China as that reported in the US study.[48]

The pilot is limited in three ways. First, the response rate for the pilot was not high—about 32%. The response rate may have been driven down by the fact that many of the participants with a rural Hukou (about half of the total sample of people) live and work in cities, which might make it more difficult for them to participate in the study. In addition, participation was entirely voluntary, which may also have driven down the response rate. However, because of its large size, we believe that our sample is large enough to capture the full diversity of the Chinese population. Our response rate is also consistent with and a modest improvement over that seen in the China Kadoorie Biobank, a study that employed similar recruitment strategies.[37] And it is a significant improvement over the low response rate seen in Europe for similar studies, such as the UK Biobank study (5–10%)[49] and a study that constructed a nationwide biobank in Estonia (~5%).[50] Second, since the pilot was conducted primarily to test the feasibility of a large-scale screening programme, a convenient rather than nationally representative sample was used to ensure rapid and sizable recruitment. However, in the full phase, random sampling will be used to select a nationally representative sample. Third, no medication or lifestyle interventions were offered to high-risk subjects in the pilot phase. Instead, only general recommendations on lifestyle changes were provided, as it would be unrealistic to properly evaluate the efficacy of any such intervention after only a 1-month follow-up. Nevertheless, these limitations are minor considering the scope of the pilot project. The project's use of a rigorous methodological design and thorough data collection methodologies ensure its ability to act as a resource for future investigation into the prevention of CVD.

As the incidence rate of CVD increases nationwide, it is critical for China to acknowledge, contain and counteract the threat that CVD poses to the nation's long-term health and economic well-being. As the first large-scale screening initiative of its kind, the pilot will provide a powerful first step for China in this process. This pilot will demonstrate the feasibility of conducting a large-scale screening effort with research-grade methods. Consequently, it will lay the foundation for future national CVD prevention and intervention studies and has the ability to promote meaningful national efforts to improve cardiovascular, and overall, health.

Author affiliations
[1]National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China
[2]Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut, USA
[3]Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut, USA
[4]Section of Cardiovascular Medicine, Robert Wood Johnson Clinical Scholars Program, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA

Acknowledgements We appreciate the multiple contributions made by project teams at the National Center for Cardiovascular Diseases and the Yale-New Haven Hospital Center for Outcomes Research and Evaluation in the realms of project design and operations. We appreciate the advice from Weiwei Chen, Yang Yang, Zhengming Chen, Yu Guo, Ralph Horwitz and Sharon-Lise Normand. We thank Xingguo Sun and Hao Wang for their contributions on ECG and cardiac and carotid ultrasound examination protocol, respectively. We thank Yuan Lu, Emily Gudbranson and Hui Qu for their contributions to the manuscript. We thank all provincial and regional staff, officers in the four provinces (Liaoning, Jilin, Zhejiang and Guangxi), for their collection of data and biosamples. We thank all the subjects for their participation. We are grateful for the support provided by the Chinese government.

Contributors HMK and LJ conceived of the screening for subjects with high CVD risk and take responsibility for all aspects of it. LJ, HMK, JL and CW designed the project. JL and SX wrote the first draft of the article, with further contributions from NSD, CW, LL, HMK and LJ. CW and JL performed statistical analysis. All authors approved the final version of the article.

Funding This project is a major public health service project supported by the Ministry of Finance of China and National Health and Family Planning Commission of China, and the National Key Technology R&D Program (2013BAI09B01) from the Ministry of Science and Technology of China. HMK is supported by grant U01 HL105270-05 (Center for Cardiovascular Outcomes Research at Yale University) from the National Heart, Lung, and Blood Institute. The sponsors had no role in the conduct of the study, the collection, management, analysis and interpretation of the data, or the preparation or approval of the manuscript.

Competing interests HMK works under contract with the Centers for Medicare & Medicaid Services to develop and maintain performance measures, is chair of a cardiac scientific advisory board for UnitedHealth, and is the recipient of research grants from Medtronic and Johnson & Johnson through Yale University.

Patient consent Obtained.

Ethics approval The central ethics committee at the National Center for Cardiovascular Disease (NCCD) approved the pilot (Trial Registration Number NCT02536456).

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

1. National Research Council. *Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease*. Washington DC: National Academies Press, 2011.
2. Bi Y, Jiang Y, He J, *et al*. Status of cardiovascular health in Chinese adults. *J Am Coll Cardiol* 2015;65:1013–25.
3. He J, Gu D, Chen J, *et al*. Premature deaths attributable to blood pressure in China: a prospective cohort study. *Lancet* 2009;374:1765–72.
4. Odegaard AO, Koh WP, Yuan JM, *et al*. Western-style fast food intake and cardiometabolic risk in an Eastern country. *Circulation* 2012;126:182–8.
5. He J, Gu D, Wu X, *et al*. Major causes of death among men and women in China. *N Engl J Med* 2005;353:1124–34.
6. Popkin BM. Synthesis and implications: China's nutrition transition in the context of changes across other low- and middle-income countries. *Obes Rev* 2014;15(Suppl 1):60–7.
7. Wang X-Q, Chen P-J. Population ageing challenges health care in China. *Lancet* 2014;383:870.
8. Moran A, Gu D, Zhao D, *et al*. Future cardiovascular disease in China: Markov model and risk factor scenario projections from the coronary heart disease policy model-china. *Circ Cardiovasc Qual Outcomes* 2010;3:243–52.
9. Wang S, Marquez P, Langenbrunner J. *Toward a healthy and harmonious life in China: stemming the rising tide of non-communicable diseases*. Washington: The World Bank, 2011.
10. Eckel RH, Jakicic JM, Ard JD, *et al*. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. *Circulation* 2014;129(25_Suppl_2): S76–99.
11. Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. [Chinese guidelines for prevention of cardiovascular diseases]. *Zhonghua Xin Xue Guan Bing Za Zhi* 2011;39:3–22.
12. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994;344:1383–9.
13. Sacks FM, Pfeffer MA, Moye LA, *et al*. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. *N Engl J Med* 1996;335:1001–9.
14. Tonkin A, Aylward P, Colquhoun D, *et al*. Prevention of cardiovascular events and death with Pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *N Engl J Med* 1998;339:1349–57.
15. Baigent C, Keech A, Kearney PM, *et al*., Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet* 2005;366:1267–78.
16. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 2000;283:1967–75.
17. Psaty BM, Lumley T, Furberg CD, *et al*. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. *JAMA* 2003;289:2534–44.
18. Clair C, Rigotti NA, Porneala B, *et al*. Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. *JAMA* 2013;309:1014–21.
19. Kodama S, Tanaka S, Heianza, Y, *et al*. Association between physical activity and risk of all-cause mortality and cardiovascular disease in patients with diabetes: a meta-analysis. *Diabetes Care* 2013;36:471–9.
20. Shortreed SM, Peeters A, Forbes AB. Estimating the effect of long-term physical activity on cardiovascular disease and mortality: evidence from the Framingham Heart Study. *Heart* 2013;99:649–54.
21. Cook NR, Cutler JA, Obarzanek E, *et al*. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). *BMJ* 2007;334:885–8.
22. Yu-Poth S, Zhao G, Etherton T, *et al*. Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. *Am J Clin Nutr* 1999;69:632–46.
23. Ness AR, Powles JW. Fruit and vegetables, and cardiovascular disease: a review. *Int J Epidemiol* 1997;26:1–13.
24. Berger JS, Jordan CO, Lloyd-Jones D, *et al*. Screening for cardiovascular risk in asymptomatic patients. *J Am Coll Cardiol* 2010;55:1169–77.
25. American College of Cardiology. Matching the intensity of risk factor management with the hazard for coronary disease events. *J Am Coll Cardiol* 1995;96:957–1047.
26. Greenland P, Alpert JS, Beller GA, *et al*. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2010;122:e584–636.
27. Xu Y, Wang L, He J, *et al*. Prevalence and control of diabetes in Chinese adults. *JAMA* 2013;310:948–59.
28. Wang S, Xu L, Jonas JB, *et al*. Prevalence and associated factors of dyslipidemia in the adult Chinese population. *PLoS ONE* 2011;6: e17326.
29. Wang H, Zhang X, Zhang J, *et al*. Factors associated with prevalence, awareness, treatment and control of hypertension among adults in Southern China: a community-based, cross-sectional survey. *PLoS ONE* 2013;8:e62469.
30. Wei X, Zou G, Yin J, *et al*. Characteristics of high risk people with cardiovascular disease in Chinese rural areas: clinical indictors, disease patterns and drug treatment. *PLoS ONE* 2013;8: e54169.
31. Dharmarajan K, Li J, Li X, *et al*. The China Patient-Centered Evaluative Assessment of Cardiac Events (China PEACE) retrospective study of acute myocardial infarction: study design. *Circ Cardiovasc Qual Outcomes* 2013;6:732–40.
32. Li J, Dharmarajan K, Li X, *et al*. Protocol for the China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) retrospective study of coronary catheterisation and percutaneous coronary intervention. *BMJ Open* 2014;4:e004595.
33. Collins FS, Varmus H. A new initiative on precision medicine. *N Engl J Med* 2015;372:793–5.
34. World Health Organization. Prevention of cardiovascular disease. Guidelines for assessment and management of cardiovascular risk. Geneva: WHO, 2007.
35. World Health Organization/International Society of Hypertension. *WHO/ISH Risk prediction charts for 14 WHO epidemiological sub-regions*. Geneva: WHO, 2007.
36. Bidgood WD, Horii SC, Prior FW, *et al*. Understanding and using DICOM, the data interchange standard for biomedical imaging. *J Am Med Inform Assoc* 1997;4:199–212.
37. Chen Z, Chen J, Collins R, *et al*. China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up. *Int J Epidemiol* 2011;40: 1652–66.
38. Li Q, Babor TF, Hao W, *et al*. The Chinese translations of Alcohol Use Disorders Identification Test (AUDIT) in China: a systematic review. *Alcohol Alcohol* 2011;46:416–23.
39. Zhao Y, Strauss J, Yang G, *et al*. *China Health and Retirement Longitudinal Study—2011–2012 national baseline users' guide*. Beijing: National School of Development, Peking University, 2013.
40. Wang HM, Patrick DL, Edwards TC, *et al*. Validation of the EQ-5D in a general population sample in urban China. *Qual Life Res* 2012;21:155–60.
41. Strauss J, Lei X, Park A, *et al*. Health outcomes and socio-economic status among the elderly in Gansu and Zhejiang Provinces, China: evidence from the CHARLS pilot. *J Popul Ageing* 2010;3:111–42.
42. Yang ZJ, Liu J, Ge JP, *et al*. Prevalence of cardiovascular disease risk factor in the Chinese population: the 2007–2008 China National Diabetes and Metabolic Disorders Study. *Eur Heart J* 2012;33:213–20.
43. Gu D, Gupta A, Muntner P, *et al*. Prevalence of cardiovascular disease risk factor clustering among the adult population of China: results from the International Collaborative Study of Cardiovascular Disease in Asia (InterAsia). *Circulation* 2005;112:658–65.
44. Wang Y, Mi J, Shan XY, *et al*. Is China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in China. *Int J Obes (Lond)* 2007;31:177–88.

45. Wu Y, Huxley R, Li L, *et al*. Prevalence, awareness, treatment, and control of hypertension in China: data from the China National Nutrition and Health Survey 2002. *Circulation* 2008;118:2679–86.
46. Yang G, Fan L, Tan J, *et al*. Smoking in China: findings of the 1996 National Prevalence Survey. *JAMA* 1999;282:1247–53.
47. Flegal KM, Carroll MD, Kit BK, *et al*. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. *JAMA* 2012;307:491–7.
48. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. *JAMA* 2010;303:2043–50.
49. Manolio TA, Weis BK, Cowie CC, *et al*. New models for large prospective studies: is there a better way? *Am J Epidemiol* 2012;175:859–66.
50. Leitsalu L, Haller T, Esko T, *et al*. Cohort profile: Estonian Biobank of the Estonian Genome Center, University of Tartu. *Int J Epidemiol* 2015;44:1137–47.

Erratum: *Protocol for the China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) Million Persons Project pilot*

Lu J, Xuan S, Downing NS, *et al*. Protocol for the China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) Million Persons Project pilot. *BMJ Open* 2015;5:e010200. There is an error in the last two rows of table 3. The number and percent of haemorrhage stroke and ischaemic stroke were reversed in total and gender subgroups. The correct table 3 is given below.

Table 3 Anthropometric parameters and medical history of screening subjects in four provinces

	Male (N=42469)		Female (N=57531)		Total (N=10000)	
	N or mean	% or SD	N or mean	N or mean	% or SD	N or mean
Height (cm)	166.81	6.91	156.22	6.42	160.72	8.45
Weight (kg)	68.22	10.34	59.21	9.39	63.03	10.77
BMI (kg/m^2)	24.46	3.05	24.23	3.36	24.33	3.24
<18.5	583	1.37%	1449	2.52%	2032	2.03%
18.5–24.9	25237	59.42%	34903	60.67%	60140	60.14%
25.0–29.9	14656	34.51%	17984	31.26%	32640	32.64%
≥30.0	1974	4.65%	3195	5.55%	5169	5.17%
SBP (mm Hg)	140.53	19.33	138.96	20.54	139.63	20.05
DBP (mm Hg)	82.91	10.78	80.10	10.80	81.29	10.88
High blood pressure*	20193	47.55%	25275	43.93%	45468	45.47%
TC (mmol/L)	4.65	1.02	5.01	1.12	4.86	1.09
TG (mmol/L)	1.88	1.17	2.02	1.19	1.96	1.18
HDL (mmol/L)	1.44	0.46	1.58	0.45	1.52	0.46
LDL (mmol/L)	2.50	0.84	2.65	0.90	2.58	0.88
Medical history						
Hypertension	8254	19.44%	12602	21.90%	20856	20.86%
Diabetes	2197	5.17%	3536	6.15%	5733	5.73%
Myocardial infarction	512	1.21%	486	0.84%	998	1.00%
PCI	272	0.64%	143	0.25%	415	0.42%
CABG	39	0.09%	31	0.05%	70	0.07%
Stroke	2031	4.78%	2466	4.29%	4497	4.50%
Hemorrhage stroke	194	0.46%	161	0.28%	355	0.36%
Ischemic stroke	1604	3.78%	2016	3.50%	3620	3.62%

Values are n (%) or mean (SD) as indicated.
*χ^2 test for proportion and two-tailed t test (or t' test if equal variances not assumed) for means, α=0.05.
†High blood pressure: SBP ≥140 mm Hg or DBP ≥90 mm Hg.
BMI, body mass index; CABG, coronary artery bypass grafting; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride.

BMJ Open 2016;**6**:e010200corr1. doi:10.1136/bmjopen-2015-010200corr1

SUPPLEMENTAL MATERIAL

Title: Protocol for the China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) Millions Persons Project-Pilot

Jiapeng Lu[1], Si Xuan[2, 4],Nicholas S, Downing[2], Chaoqun Wu[1], Li Li[1], Harlan M. Krumholz[2, 3, 4], Lixin Jiang[1,*]

[1] National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China;
[2] Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut, United States;
[3]Section of Cardiovascular Medicine, Robert Wood Johnson Clinical Scholars Program, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, United States;
[4]Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut, United States.

*** Corresponding author:**
Professor Lixin Jiang
National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, 167 Beilishi Road, Beijing 100037, People's Republic of China; Tel: +86 10 8839 6203;Email: jiangl@fwoxford.org

Table of Contents

Appendix 1 Informed consent agreement

Appendix 2 General information questionnaire

Appendix 3 Initial screening questionnaire

Appendix 4 Report of initial screening

Appendix 5 Echocardiogram report

Appendix 6 Carotid artery ultrasound report

Appendix 7 High-risk subjects questionnaire

Appendix 8 Report of assessment for high-risk subjects

Appendix 9 Report of follow-up assessment

Appendix 10 Follow-up questionnaire

Appendix 11 Table of predefined ranges for measurement variables

Appendix 12 Date management and security protocol

Appendix 1 Informed consent agreement

You are invited to participate in the Program of Screening and Intervention of Subjects with High Cardiovascular Disease Risk, which was approved by the Ministry of Finance and the National Health and Family Planning Commission (NHFPC). The program was conducted by local governments who received subsidies from the federal governments. The NHFPC Bureau of Disease Prevention and Control, the National Center for Cardiovascular Disease (NCCD), and the local Health and Family Planning Commission collaborated to launch the program. The ethics committees of the Fuwai hospital and the NCCD approved the protocol and procedures of the program. Please carefully read the following information before you decide whether or not to participate. If you have any questions, please feel free to ask our personnel. Your participation is entirely voluntary, and you have the right to not participate or to withdraw at any time without any particular reason. Withdrawal will not result in any penalty or the loss of benefits to which you are entitled.

Cardiovascular disease has become a major public health challenge in China. The early detection and treatment of subjects with high cardiovascular disease risk have been identified as key strategies in the prevention of cardiovascular disease. Therefore, the program aims to screen 0.4 million residents and identify high-risk subjects who will receive health assessments, health counseling, and follow-ups.The program takes place in four provinces, with each province selecting 5 study sites. The community (village) in which you live is one of the study sites. Each study site has invited 20,000 residents to participate, and you are one of them. You do not need to pay for any expenses during your participation. The Ministry of Finance will be responsible for all your expense during the program.

If you decide to participate in the program, you will be asked questions by our staff regarding basic identifiers (e.g., age, gender) and your cardiovascular-related health status. To assess your risk of cardiovascular disease, your blood pressure, height, and weight will be measured, and a lipid blood test (fingertip blood sample) will be performed. If you are identified as a subject with a high risk of cardiovascular disease, our personnel will ask you about details of your cardiovascular-related health status. A 12-lead electrocardiogram (ECG), an echocardiogram, and a carotid artery ultrasound will then be performed. In addition, a 10mL whole blood sample and a 20mL urine sample will be collected for a blood biochemistry test, a hemoglobin A1c (HbA1C) test, and a urine routine test. After assessment, you will have a follow-up appointment that includes an assessment of your cardiovascular health status, a physical examination, and an ECG. All of your physical measurement results will be provided directly to you. Blood and urine samples will be transported to the NCCD for long-term storage and may be used in future biochemical, biological, and genetics research.

All physical measurements are non-invasive. You may feel slight pain during the collection of the finger-tip blood sample and the whole blood sample, but it will not cause any harm to your health. Fainting at the sight of blood or needles may occasionally occur. Trained medical staff members who are capable of handling emergency situations perform all blood collections.

The information that you provide will be securely stored in an encrypted and password-protected database at the NCCD and will be kept confidential. Only the senior program manager and the government supervisor have access to the database, and they can only access it using their individual passwords. Only the results of the whole sample will be disseminated, and no personal information will be made public.

Trained staff members conduct all assessments of cardiovascular health status, physical measurements, bio-samples, and lab tests. They will thoroughly answer any questions you may have. All examinations (include blood/urine lab tests) are free. The assessments can help you better understand your health status and risk of cardiovascular disease. If you are identified as at high risk of cardiovascular disease, our medical staff members will provide suggestions about beneficial lifestyle and medication changes based on your health assessment, though we are not responsible for the costs of any recommended medications or treatments. This program will not only benefit the participants, but will also inform approaches to health promotion and policy decision-making efforts on the screening and subsequent management of people early in the course of CVD.

If you have any further question, please feel free to contact us at010-6086 6783.

Certificate of consent：

I have read the aforementioned information, including the purposes, procedures, risks, and benefits of the program. I have had the opportunity to ask questions about the program, and any questions that I have asked have been answered satisfactorily. I consent to participate in the Programme of Screening and Intervention Subjects with High Risk of Cardiovascular Disease.

Screening (includes assessment of cardiovascular health, physical measurements, and blood/urine lab tests): Agree ☐ Do not agree ☐

Long term storage of blood/urine sample for future research: Agree ☐ Do not agree ☐

Participant signature: _____ **Date**：_____Year____Month_____Day

I have accurately explained the purposes of the program to the potential participant, and have correctly answered any questions asked by the participant. I confirm that the participant understands the purposes, procedures, risks, and benefits of the program.

Staff signature: _____ **Date**：_____Year____Month_____Day

Appendix 2 General information questionnaire

1. Demographic Information	
1.1	**Name**: _____
1.2	**Gender**○ Male ○ Female
1.3	**Ethnicity**: _____
1.4	**Date of birth**□□□□Year □□Month □□Day
1.5	**ID number**□□□□□□□□□□□□□□□□□□
1.6	**Other ID number**: _____
1.7	**Current Hukou status** ○ Agriculture Hukou ○ Non-Agriculture Hukou ○ Unified Residency Hukou ○ Does not have Hukou
1.8	**Marital status** ○ Married and cohabiting with spouse ○ Married but temporarily living separately from spouse ○ Separated ○ Divorced ○ Widowed ○ Never married ○ Unknown ○ Refused to answer
1.9	**Education** ○ Illiterate ○ Less than elementary school level, but can read and write ○Si Shu ○ Graduate from elementary school ○ Graduate from middle school ○ Graduate from high school ○ Graduate from vocational school ○Graduate from junior college ○ Graduate from four-year College / Bachelor's degree

	○ Graduate from Graduate school/Master's degree ○ Graduate from Graduate school/PhD ○ Unknown ○ Refused to answer
1.10	**Employment Status** ○ Farmer ○ Workers ○ Administrator or manager ○ Administrative clerk ○ Professional technician ○ Businessman or service industry worker ○ Self-employed ○ Military ○ Other ○ Unemployed ○ Retired ○ Housekeeper ○ Unknown ○ Refused to answer
1.11	**What was your total household income in the last year (rmb)?** ○< 5,000 ○ 5,000 – 9,999 ○ 10,000 - 19,999 ○ 20,000-50,000 ○> 50,000 ○ Unknown ○ Refused to answer
1.12	**What types of medical insurance do you have? (You may choose more than one)** ○Urban resident medical insurance ○Urban employee medical insurance ○New cooperative medical insurance ○Urban and rural resident medical insurance ○Medical aid ○Private medical insurance: purchased by R's union ○Government-sponsored medical insurance ○Self-insured ○Private medical insurance: purchased by Individual

	○Other medical insurance (specify):_____ ○No insurance ○ Unknown
1.13	**[If any type of medical insurance in 1.12 was chosen] Medical insurance number**: _____
2. Contact Information	
2.1	**Address:** Province CityDistrictStreetHouse number
2.2	**Home phone number**: _____
2.3	**Cell phone number**: _____
2.4	**Emergency contact name**: _____
2.5	**Relationshipto you:** ○ Parent○ Children ○ Sibling○ spouse○ Others
2.6	**Emergency contact phone number**: _____

Appendix 3 Initial screening questionnaire

1. Basic Information	
1.1	**Age:** □□ Years
1.2	**Gender**○ Male ○ Female
2. Smoking	
2.1	**Do you currently smoke cigarettes?** ○ Yes ○ No
2.2	**[If you answer "Yes" to 2.1] How many cigarettes per day did you smoke?** _____number/day
3. Alcohol	
3.1	**During the past year, how frequentlydid you drink alcohol?** ○ Never ○ Once a month or less ○ 2 to 4 times a month ○ 2 to 3 times a week ○ 4 or more times a week ○ Unknown ○ Refused to answer
4. History of Disease	
4.1	**Have you been diagnosed with, or received treatment for, any of the following:** ○ Hypertension (diagnosed or have taken anti-hypertension medication) The definite diagnosis till now _ _ _ _ _ year ○ Diabetes (diagnosed or have taken anti-diabetics or injection of insulin) The definite diagnosis till now _ _ _ _ _ year ○ Myocardial Infarction The definite diagnosis till now _ _ _ _ _ year ○ Percutaneous Coronary Intervention (PCI) Performed in _ _ _ _ _ (date) ○ Coronary Artery Bypass Grafting(CABG) Performed in _ _ _ _ _ (date) ○ Stroke The definite diagnosis till now _ _ _ _ _ year ○ None

4.2	**[If "stroke" was chosen in 4.1] What was the type of stroke?** ○ Ischemic Stroke ○ Hemorrhagic Stroke ○ Unknown
5. History of Medication	
5.1	**Have you taken any medications (anti-hypertension, lipid-lowering, anti-diabetics and anti-platelet) in the past 2 weeks?** ○ Yes ○ No
5.2	**[If you answered yes to 5.1] medication name:**_____ (Choose from lists of medication)
5.3	**Dose:**_____
5.4	**Unit:**○ g ○ mg ○ ml ○ u ○pill ○ Other ○ Unknown
5.5	**Frequency:** ○ 1 time/day (Qd /QN) ○ 2 times/day (Bid/q12h) ○ 3 times/day (Tid/q8h) ○ 4 times/day (Q6h) ○ 1 times per 2 days (Qod) ○ Taken whenever necessary (sos/prn) ○ Other ○ Unknown
5.6	**[If you answered yes to 5.1] how often do you take the above-stated medication(s)?** ○ Everyday ○ Always ○ Sometimes
5.7	**Have you taken any of the traditional Chinese medicines listed below in the past 2 weeks?** ○ Anti-hypertension ○ Anti-diabetics ○ Lipid lowering ○ Anti-platelet ○ None
6. Identify special cases	

6.1	**Did any of your siblings, parents, aunts, uncles, grandparents, or great grandparents live to be older than 90?** ○ None ○ 1 person ○ More than 1 person ○ Unknown
6.2	**Did any of your children, siblings, parents, aunts, uncles, or grandparents have cardiovascular disease (CVD) before the age of 50?** ○ None ○ 1 person ○ More than 1 person, and at least 2 persons had the same type CVD ○ More than 1 person, and at least 2 types of CVD or unknown types of CVD ○ Unknown
6.3	**Did any of your children, siblings, parents, aunts, uncles, or grandparents pass away due to cardiovascular disease (CVD) before the age of 50?** ○ None ○ 1 person ○ More than 1 person, and at least 2 persons' deaths were due to the same type of CVD ○ More than 1 person, and deaths due to more than 1 type of CVD or unknown types of CVD ○ Unknown
6.4	**Did any of your children, siblings, parents, aunts, uncles, or grandparents die suddenly due to unknown reasons (except for accidental death) before the age of 50?** ○ None ○ 1 person ○ More than 1 person ○ Unknown
6.5	**Did you or any of your children, siblings, parents, aunts, uncles, or grandparents develop cancer before the age of 50?** ○ None ○ 1 person ○ More than 1 person, and at least 2 persons had the same type of cancer (e.g., both lung cancer) ○ More than 1 person, and more than 1 type of cancer, or unknown specific names of cancer ○ Unknown
6.6	**Did you or any of your children, siblings, parents, aunts, uncles, or grandparents experience a stroke before the age of 50?** ○ None ○ 1 person

	○ More than 1 person, and at least 2 persons had the same type of stroke (e.g., both ischemic stroke or both hemorrhage stroke) ○ More than 1 person, and more than 1 type of stroke or unknown types of stroke ○ Unknown
7. Results of Initial Screening (system-generated)	
7.1	**CVD risk assessment:** ○ High CVD risk (established CVD) ○ High CVD risk (high blood pressure) ○ High CVD risk (dyslipidemia) ○ High CVD risk (10-year risk of CVD ≥ 20%) ○ Non high CVD risk
8. Recommendations about lifestyle change (system-generated)	
8.1	**Recommendations:** ○ Healthy, low-fat diet ○ Weight loss ○ Regular physical activity ○ Smoking cessation ○ Limit alcohol ○Healthy daily routine with sufficient sleep ○ Routine annual physical examination ○ Recommend potential cardiovascular disease patient for further diagnose and treatment

Appendix 4 Report of initial screening

1. Personal Information

Name: _____ Gender: □ Male □ Female Age: □□

2. Blood Pressure & Heart Rate

	First Measurement	Second Measurement	Mean
Systolic Blood Pressure	□□□	□□□	□□□ mmHg
Diastolic Blood Pressure	□□□	□□□	□□□ mmHg
Heart Rate	□□□	□□□	□□□ beats/minute

3. Blood Lipid

Total cholesterol (TC): □□□.□□ mmol/L

Triglyceride (TG): □□□.□□ mmol/L

High density lipoprotein cholesterol (HDL-C): □□□.□□ mmol/L

Low density lipoprotein cholesterol (LDL-C): □□□.□□ mmol/L

4. Height & Weight

Height: □□□.□ cm Weight: □□□.□ kg BMI: □□.□ kg/m^2

5. Evaluation of Cardiovascular Disease Risk

□ High risk □ Non-high risk

6. Recommendations for healthy lifestyle

□ Healthy, low-fat diet

□ Weight loss

□ Regular physical activity

□ Smoking cessation

□ Limit alcohol

□Healthy daily routine with sufficient sleep

□ Routine annual physical examination

□ Recommend potential cardiovascular disease patient for further diagnose and treatment

Investigator Signature: _____ Date: □□□□ Year □□ Month □□ Day

Appendix 5 Echocardiogram report

1. Personal Information

Name:____ ID: _____ Gender: □ Male □ Female Date：□□□□ Year □□ Month □□ Day

2. Two dimensional & M-mode measurements (mm)

Aorta

Aortic valve annulus diameter□□□ Ascending aorta diameter□□□

Left ventricle

Anterior-posterior diameter □□□ Diastole □□□ LVPW □□□ LVEF □□□

Right ventricle

Anterior-posterior diameter□□□

IVS□□□

TAPSE□□□

Simpson EF□□□

3. Valve leaflet (leave blank if normal)

Structure	Forward flow velocity (m/s)	Differential pressure (mmHg)	Regurgitation	Regurgitation velocity (m/s)	Pressure gradient (mmHg)
Mitral valve	□□□	□□□		□□□	□□□
Tricuspid valve	□□□	□□□		□□□	□□□
Aorta valve	□□□	□□□		□□□	□□□
Pulmonary valve	□□□	□□□		□□□	□□□

4. Positive (leave blank if normal)

5. Imaging

Appendix 6 Carotid artery ultrasound report

1. Personal Information

Name: _____ ID: _____ Gender: □ Male □ Female Date：□□□□ Year □□ Month □□ Day

2. **Left**

CCA-IMT (mm)

Near wall □□□ Middle wall□□□ Far wall□□□

Plaque (mm, leave blank if normal)

Quantity (1=single, 2=multiple) □□□

Length of maximum plaque □□□Thickness of maximum plaque□□□

Shape (1=regular, 2=irregular) □□□Ulcer (0=no, 1=yes)□□□

Morphology (homogeneous: A1=hypoechoic, A2=isoechoic, A3=hyperechoic; B=heterogeneous)□□□

Lumen stenosis (%)

Stenosis area

3. Right

CCA-IMT (mm)

Near wall □□□ Middle wall□□□ Far wall□□□

Plaque (mm, leave blank if normal)

Quantity (1=single, 2=multiple) □□□

Length of maximum plaque □□□Thickness of maximum plaque□□□

Shape (1=regular, 2=irregular) □□□Ulcer (0=no, 1=yes)□□□

Morphology (homogeneous: A1=hypoechoic, A2=isoechoic, A3=hyperechoic; B=heterogeneous)□□□

Lumen stenosis (%)

Stenosis area

4. Imaging

Appendix 7 High-risk subjects questionnaire

1. Smoking	
1.1	**How often do you currently smoke tobacco?** ○ Do not smoke ○ Occasionally ○ Most days **[go to 1.6]** ○ Daily or almost every day **[go to 1.6]**
1.2	**In the past, how frequently did you smoke?** ○ Did not smoke ○ Smoked only occasionally ○ Smoked on most days **[go to 1.4]** ○ Smoked daily or almost every day **[go to 1.4]**
1.3	**In your lifetime, have you smoked a total of at least 100 cigarettes?[go to alcohol section]** ○ Yes ○ No
1.4	**How many years ago did you last stop smoking regularly?**□□ Years□□ Month
1.5	**What was your main reason for quitting smoking?** ○Pre-existing physical illness ○ Family opposition to smoking ○Financial burden of smoking ○ Other ○ Health concerns related to smoking
1.6	**At about what age did you first start smoking on most days?** □□ Years
1.7	**What tobacco type did you use when you first started smoking on most days?** ○ Cigarette ○ Other ○ Mixed types
1.8	**[If you choose "Cigarette" in 1.7] Since beginning to smoke, have you not ever smokefor one month?** ○ Yes ○ No

1.9	**What type of tobacco do you smoke (either now or before quitting), and how much tobacco do you usually smoke?** ○Filtered cigarettes ___ number/day ○Non-filtered cigarettes ___ number/day ○Hand-rolled cigarettes ___ liang/month ○Pipe or hookah water ___ liang/month ○Cigars ___ number/day
1.10	**How deeply do you usually inhale the smoke?** ○ Mouth only ○ Throat ○ Lung
1.11	**[If you choose "Lung" in 1.10] Have you always inhaled the smoke into your lungs when smoking?** ○ Yes ○ No
1.12	**Has your tobacco consumption changed significantly compared toseveral years ago?** ○ About the same as before ○ Has increased significantly ○ Has decreased significantly
2. Alcohol	
2.1	**How often do you drink alcohol?** ○ Never **[go to 2.5]** ○ Once a monthly or less ○ 2 to 4 times a month ○ 2 to 3 times a week ○ 4 or more times a week ○ Unknown ○ Refused to answer
2.2	**How many drinks containing alcohol do you have on a typical day when you are drinking?** ***1 unit means 17mL hard alcohol, 120mL wine, 360mL beer, 100mL Huangjiu, or 45mL Baijiu*** ○ 1-2 ○ 3-4 ○ 5-6 ○ 7-9 ○ 10 or more ○ Unknown ○ Refused to answer

2.3	**How often do you have six or more drinks in one sitting?** ○ Never ○ Less than once a month ○ Monthly ○ Weekly ○ Daily or almost daily ○ Unknown ○ Refused to answer					
2.4	**How often during the past year have you felt the following? [If 2.2 "1 or 2" and 2.3 "never", go to 2.5]**					
		Never	**Less than once per month**	**Every month**	**Every week**	**Almost very day**
a)	Unable to stop drinking once you have started?	○	○	○	○	○
b)	Unable to do what was normally expected due to drinking too much alcohol?	○	○	○	○	○
c)	You need an alcoholic drink in the morning after a heavy drinking session the night before?	○	○	○	○	○
d)	You feel guilty or remorseful after drinking?	○	○	○	○	○
e)	You are unable to remember what happened the night before due to drinking?	○	○	○	○	○
2.5	**Have you ever been injured, or have you injured someone else, due to your drinking?** ○ No ○ Yes, but not in the past year ○ Yes, during the past year ○ Unknown ○ Refused to answer					

2.6	**Has a relative, friend, doctor, or other health worker been concerned about your drinking behavior orsuggested you cut down on your drinking?** ○ No ○ Yes, but not in the past year ○ Yes, during the past year ○ Unknown ○ Refused to answer
3.0	**What type of worker are you?** ○ Non-agricultural worker **[go to 3.1]** ○ Agricultural worker **[go to 3.5]**
3. Physical activity (Non-agricultural worker)	
3.1	**During the past 12 months, how active were you at work?** ○ Mainly sedentary (e.g., administrator, clerk) ○ Standing occupation (e.g., salesman, guard) ○ Manual work (e.g., pipe, electrician, wood, bricklayer) ○ Heavy manual work (e.g., mining, steelmaking) ○ Retiree, housewife/husband, unemployed, or disabled **[go to 3.12]**
3.2	**In a typical week, about how many hours do you usually work?** _____ hours
3.3	**During the past 12 months, how did you usually get to work?** ○ Mainly by walking ○ By motorbike ○ By bicycle ○ By bus/car/ferry/train ○ I mainly stayed at home or worked near home **[go to 3.12]**
3.4	**How much time did you spend each day commuting to and from work?** _____minutes
3. Physical activity (Agricultural worker)	
3.5	**During the past 12 months, did your farming work change seasonally?** ○ Yes ○ No **[go to 3.7]**

3.6	**During the farming season of the past 12 months:** **How many months did the season last?** ____months **What types of work did it usually involve?** ○ manual ○ semi-mechanized ○ fully mechanized **How many hours did you usually work each day?** ____hours **How many hours did you sweat or have a much faster than normal heartbeat?** _____ hours
3.7	**In a typical week, how many hours did you usually work in the fields?** _____ hours/week
3.8	**Apart from agriculture work, did you have any other job?** ○ Yes ○ No **[go to 3.11]**
3.9	**How active were you at work in your other job?** ○ Mainly sedentary (e.g., knit, sewing) ○ Mainly standing (e.g., guard, salesman) ○ Mainly general manual work (e.g., pipe, electrician, wood, bricklayer) ○ Mainly heavy manual work(e.g., porter, mining, stevedore)
3.10	**In a typical week, about how many hours did you work at your other job?** ____ hours
3.11	**In a typical day, how much time did you usually spend commuting to and from work on foot or by bicycle?** _____minutes
3. Physical activity (common forboth agricultural and non-agricultural workers)	
3.12	**During the past 12 months, how frequently did you exercise in your leisure time?** ○ Never or almost never **[go to 3.15]** ○ 1-3 times/month **[go to 3.15]** ○ 1-2 times/week ○ 3-5 times/week ○ Daily or almost every day
3.13	**If you exercise every week, what is your main type of exercise?** ○ Taichi/Qigong ○ Jogging/aerobic exercise ○ Ball games (e.g., basketball, table tennis) ○ Walking ○ Swimming ○ Other (e.g., Mountain climbing)
3.14	**About how many hours per week did you spend doing such exercise in your leisure time?** _____ hours/weeks

3.15	**In a typical week during the past 12 months, how often did you sweat or have a much faster heartbeat than normal because of heavy physical exertion/exercises?** ○ Never or almost never**[go to 3.17]** ○ < 1 times/week**[go to 3.17]** ○ 1-2 times/week ○ 3-5 times/week ○ Daily or almost every day
3.16	**About how many hours per week did you do such activities?** ____ hours/weeks
3.17	**About how many hours per week did you do housework (include look after children)?** ____ hours/weeks
3.18	**About how many hours per week did you watch TV, read, play card, or knit?** ____ hours/weeks
3.19	**During the past 12 months, has your weight changed significantly?** ○ About the same as before ○ Yes, I've gained ≥2.5kg ○ Yes, I've lost ≥2.5kg
3.20	**Have you tried to reduce your weight by diet or medication in the past 12 months?** ○ Yes ○ No
3.21	**How much did you weigh when you were 25?** _____ Jin ○ Unknown

4. Diet

4.1 **During the past year, how frequently did you eat the following foods?**

	Food	Daily	4-6 days/ week	1-3 days/ week	1-3 days/ month	None or little
a)	Rice: including rice, rice porridge and rice noodles	○	○	○	○	○
b)	Wheat foods: foods containing wheat flour, such as noodles, steamed buns, bread, and pies	○	○	○	○	○
c)	Grains: all other food crops except wheat and rice, including millet, maize, sorghum	○	○	○	○	○
d)	Meat and meat products	○	○	○	○	○
e)	Poultry and poultry products	○	○	○	○	○

f)	Seafood and seafood products: including freshwater fish, shrimp, crab, and saltwater fish, shrimp, crab, and a variety of shellfish (fresh, frozen or processed)	○	○	○	○	○
g)	Eggs: fresh eggs or egg products (such as preserved eggs, salted eggs)	○	○	○	○	○
h)	Fresh vegetables	○	○	○	○	○
i)	Pickles, sauerkraut, preserved vegetables, pickled vegetables	○	○	○	○	○
j)	Fresh fruit	○	○	○	○	○
k)	Soy foods: various types of soy products (including tofu) and beverages (including soy milk) with soybean as a main raw material	○	○	○	○	○
l)	Milk and dairy foods: milk, goat's milk, yogurt, cheese, milk powder and pure dairy products	○	○	○	○	○

4.2 **During the past year, have you ever taken the following types of nutritional supplements for at least one month?*[check all that apply]***

○ Cod liver oil / fish oil
○ Multivitamins
○ Calcium / iron / zinc tablets
○Traditional Chinese health products
○ None of the above

5. History of Disease

5.1 **Have you ever been diagnosed with any of the following diseases?**

○ Angina ○ No ○Yes, been diagnosed_____years ○Unknown
○Heart Failure ○ No ○Yes, been diagnosed_____years ○Unknown
○ Valvular Heart Disease ○ No ○Yes, been diagnosed_____years ○Unknown
○ Arrhythmia ○ No ○Yes, been diagnosed_____years ○Unknown
○ Hypercholesterolemia ○ No ○Yes, been diagnosed_____years ○Unknown
○ Dyslipidemia ○ No ○Yes, been diagnosed_____years ○Unknown
○ Chronic Renal Disease ○ No ○Yes, been diagnosed_____years ○Unknown
○ Peripheral Vascular Disease ○ No ○Yes, been diagnosed_____years ○Unknown
○ Cancer (except for skin cancer) ○ No ○Yes, been diagnosed_____years ○Unknown

6. Family History of Disease

6.1	**Has your father, or any of your brothers,had any of the following diseases before turning 55?** ***[check all that apply]*** ○ Hypertension ○ Coronary Heart Disease ○ Ischemic Stroke ○ Hemorrhagic Stroke ○ Diabetes ○ Cancers ○ Hypercholesterolemia ○ None of above
6.2	**Has your mother, or any of your sisters,had any of the following diseases before turning 65?** ***[check all that apply]*** ○ Hypertension ○ Coronary Heart Disease ○ Ischemic Stroke ○ Hemorrhagic Stroke ○ Diabetes ○ Cancers ○ Hypercholesterolemia ○ None of above
7. Menstruation (female)	
7.1	**Are you in menopause?** ○ Yes ○ No ○ Refused to answer
7.2	**[If you answer "Yes" to 7.1] At what age were you in menopause?**□□ Years○ Unknown
7.3	**In the past year, have you had a menstrual period?** ○ Yes ○ No ○ Unknown ○ Refuse to answer

7.4	**[If you answer "Yes" to 7.3] In the past year, has the cycle of your menstrual period changed?** ○ Longer in duration ○ Shorter in duration ○ More irregular ○ No change ○ More regular ○ Unknown ○ Refused to answer
7.5	**When was your last menstrual period?** □□□□Year □□Month □□Day○ Unknown
7.6	**Have you ever taken a contraceptive?** ○ Yes ○ No ○ Refuse to answer
7.7	**[If you answer "Yes" to 7.6] For how many years did you take a contraceptive?** □□□□Year○ Unknown
7.8	**[If you answer "Yes" to 7.6] Are you currently taking a contraceptive?** ○ Yes ○ No ○ Refused to answer
7.9	**Have you ever taken any of the following forms of female hormone supplements?** ○ Pills ○Shots ○Implants ○Patch ○Cream ○ None of above ○ Refused to answer
7.10	**[If you chose any type of supplement in 7.9] How many years have you taken this supplement?____**_years○ Unknown
7.11	**Are you currently using this supplement?** ○ Yes ○ No ○ Refuse to answer
7.12	**[If you answer "No" to 7.11] How many years ago did you stop taking this supplement?** **____**_years○ Unknown

7.13	**Have you ever been pregnant?** ○ Yes ○ No ○ Unknown ○ Refused to answer
7.14	**[If you answer "Yes" to 7.13] Are you currently pregnant?** ○ Yes ○ No ○ Unknown ○ Refused to answer
7.15	**Have you ever had a hysterectomy and/or a bilateral oophorectomy?** ○ Yes ○ No ○ Unknown ○ Refused to answer
7.16	**[If you answer "Yes" to 7.15] Did you stop having your menstrual period immediately after the procedure?** ○ Yes ○ No ○ Unknown ○ Refused to answer
8. Health-related quality of life (EQ-5D)	
	The following questions ask about your current health status. In each of the following categories, please indicate which statement best describes your own health status today.
8.1	**Mobility** ○I have no problems walking around. ○ I have some problems walking around. ○ I am confined to bed.
8.2	**Self-care** ○I have no problems with self-care. ○ I have some problems washing or dressing myself. ○ I am unable to wash or dress myself.
8.3	**Usual activities (e.g., work, study, housework, family or leisure activities)** ○ I have no problems performing my usual activities. ○ I have some problems performing my usual activities. ○ I am unable to perform my usual activities.

8.4	**Pain/discomfort** ○I have no pain or discomfort. ○ I have moderate pain or discomfort. ○ I have extreme pain or discomfort.
8.5	**Anxiety/depression** ○I am not anxious or depressed. ○ I am moderately anxious or depressed. ○ I am extremely anxious or depressed.
8.6	Please **score** how good or poor your own health was the week before this admission. The best health state is 100 and the worst is 0. Overall, how would you score your own health today, between 0 and 100? **Enter value between 0 and 100**: _ _ _ ○ Unknown

Appendix 8 Report of assessment for high-risk subjects

1. Personal Information

Name: _____ Gender: □ Male □ Female Age: □□

2. Blood Sample Investigator ID □□

Has blood sample been collected?

EDTA vacuum tube: □ Yes □ No

Serum gel tube: □ Yes □ No

How many hours fasting (includes beverage)? □□ hours

3. Urine Sample Investigator ID □□

Has urine sample been collected? □ Yes □ No

4. ECG Investigator ID □□

Has ECG been completed? □ Yes □ No

5. Carotid artery ultrasound Investigator ID □□

Has ECG been completed? □ Yes □ No

Has participant received report of carotid artery ultrasound? □ Yes □ No

6. Echocardiography Investigator ID □□

Has echocardiography been completed? □ Yes □ No

Has participant received report of echocardiography?□ Yes □ No

7. Interview of cardiovascular health status Investigator ID □□

Has interview of cardiovascular health status been completed? □ Yes □ No

8. Recommendations for healthy lifestyle

□ Healthy, low-fat diet

□ Weight loss

□ Regular physical activity

□ Smoking cessation

□ Limit alcohol

□ Healthy daily routine with sufficient sleep

□ Routine annual physical examination □ Recommend potential cardiovascular disease patient for further diagnose and treatment □ Comply with all medication requirements
9. Medication and other suggestions:

Physician Signature：_____ Date：□□□□ Year □□ Month □□ Day

Appendix 9 Report of follow-up assessment

1. Personal Information

Name:_____ Gender: □ Male □ Female Age：□□

2. Blood Pressure & Heart Rate Investigator ID □□

	First Measurement	Second Measurement	Mean
Systolic Blood Pressure	□□□	□□□	□□□ mmHg
Diastolic Blood Pressure	□□□	□□□	□□□ mmHg
Heart Rate	□□□	□□□	□□□ beats/minute

3. Weight Investigator ID

□□

Weight: □□□.□ kg

4. ECG Investigator ID □□

Has ECG been completed? □ Yes □ No

5. Follow-up interview Investigator ID □□

Has interview of cardiovascular health status been completed? □ Yes □ No

6. Recommendations for healthy lifestyle

□ Healthy, low-fat diet

□ Weight loss

□ Regular physical activity

□ Smoking cessation

□ Limit alcohol

□Healthy daily routine with sufficient sleep

□ Routine annual physical examination

□ Recommend potential cardiovascular disease patient for further diagnose and treatment

□ Comply with all medication requirements

7. Medication and other suggestions:

PhysicianSignature：_____ Date：□□□□ Year □□ Month □□ Day

Appendix 10 Follow-up questionnaire

1. Follow-up Information	
1.1	**Date:** □□□□Year □□Month □□Day
1.2	**Interview method:**○ Face-to face interview ○ Telephone interview
1.3	**Is the interviewee actual participant?** ○ Yes **[go to 1.5]** ○ No
1.4	**Relationshipto participant:** ○ Parents ○ Children ○ Siblings ○ Spouse○ Others
1.5	**Name**: _____
1.6	**Project ID:**□□□□□□□□□□□□□□□□□□□□
1.7	**Gender:**○ Male ○ Female
2. Survival Status	
2.1	**Did subject already die?** ○ Yes ○ No
2.2	**Death Date:**□□□□Year □□Month □□Day
2.3	**Cause of death:** ○ Myocardial Infarction ○ Angina ○ Heart Failure ○ Other cardiac disease ○ Hemorrhage Stroke ○ Ischemic Stoke ○ Other Vascular Disease ○ Other_____
3. Contact Information	
3.1	**Has the personal contact information changed?** ○ Yes **[go to the personal information page for updating]** ○ No
3.2	**Have the emergency contact information changed?** ○ **Yes [go to the personal information page for updating]** ○ **No**

4. Hospitalization over the follow-up period	
4.1	**In the past month, how many times have you been hospitalized? _____times**
	The first hospitalization record
4.2	**Date of admission**: □□□□Year □□Month □□Day
4.3	**Length of stay**: _____ days
4.4	**Admission type** ○ Emergency hospital ○ Outpatient admission
4.5	**Hospital Characteristics:** ○ Community health service station ○ Town / street clinic ○ Secondary hospital ○ Tertiary hospital ○ Unknown
4.6	**The main discharge diagnosis:** ○ Myocardial Infarction ○ Unstable Angina ○ Stable Angina ○ Heart Failure ○ Arrhythmias ○ Ischemic Stroke ○ Hemorrhagic Stroke ○ Transient Ischemic Attack ○ Other: _____
4.7	**Outcome** ○ Improved ○ Not cured ○ Referral ○ Withdrew from treatment due to illness' terminal stage nature ○ Unknown
	The Second hospitalization record
4.8	**Date of admission**: □□□□Year □□Month □□Day
4.9	**Length of stay**: _____ days
4.10	**Admission type**

	○ Emergency hospital ○ Outpatient admission
4.11	**Hospital Characteristics:** ○ Community health service station ○ Town / street clinic ○ Secondary hospital ○ Tertiary hospital ○ Unknown
4.12	**The main discharge diagnosis:** ○ Myocardial Infarction ○ Unstable Angina ○ Stable Angina ○ Heart Failure ○ Arrhythmias ○ Ischemic Stroke ○ Hemorrhagic Stroke ○ Transient Ischemic Attack ○ Other: _____
4.13	**Outcome**: ○ Improved ○ Not cured ○ Referral ○ Withdrew from treatment due to illness' terminal stage nature ○ Unknown
	The Third hospitalization record
4.14	**Date of admission**: □□□□Year □□Month □□Day
4.15	**Length of stay**: _____ days
4.16	**Admission type** ○ Emergency hospital ○ Outpatient admission
4.17	**Hospital Characteristics:** ○ Community health service station ○ Town / street clinic ○ Secondary hospital ○ Tertiary hospital

	○ Unknown
4.18	**The main discharge diagnosis:** ○ Myocardial Infarction ○ Unstable Angina ○ Stable Angina ○ Heart Failure ○ Arrhythmias ○ Ischemic Stroke ○ Hemorrhagic Stroke ○ Transient Ischemic Attack ○ Other: _____
4.19	**Outcome**: ○ Improved ○ Not cured ○ Referral ○ Withdrew from treatment due to illness' terminal stage nature ○ Unknown
5. Smoking	
5.1	**Have you smokedin the past month?** ○ Yes ○ No
5.2	**[If you answer "Yes" to 5.1] How many cigarettes per day did you smoke?** _____number/day
6. Alcohol	
6.1	**Have you consumed alcohol in the past month?** ○ Yes ○ No
6.2	**[If you answer "Yes" to 6.1] How many drinks containing alcohol do you have on a typical day when you are drinking?** ***1 unit means 17mL alcohol, 120mL wine, 360mL beer, 100mL Huangjiu, or 45mL Baijiu*** ○ 1 or 2 ○ 3 or 4 ○ 5 or 6 ○ 7 - 9 ○ 10 or more ○ Unknown ○ Refused to answer

6.3	**[If you answer "Yes" to 6.1] How many times did you drink more than 6 drinks?**____times
7.0	**What type of worker are you?** ○ Non-agricultural worker **[go to 7.1]** ○ Agricultural worker **[go to 7.5]**
7. Physical activity (Non-agricultural worker)	
7.1	**During the past one-month, how active were you at work?** ○ Mainly sedentary (e.g., administrator, clerk) ○ Standing occupation (e.g., salesman, guard) ○ Manual work (e.g., pipe, electrician, wood, bricklayer) ○ Heavy manual work (e.g., mining, steelmaking) ○ Retiree, housewife/husband, unemployed, or disabled **[go to 7.12]**
7.2	**In a typical week, about how many hours do you usually work?** _____ hours
7.3	**During the past month, how did you usually commute to work?** ○ Mainly by walking ○ By motorbike ○ By bicycle ○ By bus/car/ferry/train ○ I mainly stayed at home or worked near home **[go to 7.12]**
7.4	**How much time did you spend each day commuting to and from work?** _____minutes
7. Physical activity (Agricultural worker)	
7.5	**During the past 12 months, did your farming work change seasonally?** ○ Yes ○ No **[go to 7.7]**
7.6	**During the farming season in the last 12 months:** **How many months did the season last?** ____month **What types of work did it usually involve?** ○ manual ○ semi-mechanized ○ fully mechanized **How many hours did you usually work each day?** ____hours **How many hours did you sweat or have a much faster heartbeat than normal?** _____ hours
7.7	**In a typical week, how many hours do you usually work in the field?** _____ hours
7.8	**Apart from agriculture work, did you have any other job?** ○ Yes ○ No **[go to 7.11]**

7.9	**How active are you at work for this other job?** ○ Mainly sedentary (e.g., knit, sewing) ○ Mainly standing (e.g., guard, salesman) ○ Mainly general manual work (e.g., pipe, electrician, wood, bricklayer) ○ Mainly heavy manual work(e.g., porter, mining, stevedore)
7.10	**In a typical week, about how many hours do you work at your other job?** ____ hours
7.11	**In a typical day how much time do you usually spend commuting to and from work on foot or by bicycle?** _____minutes
7. Physical activity (common to both agricultural and non-agricultural workers)	
7.12	**During the past month, how often have you exercisedduring your leisure time?** ○ Never or almost never **[go to 7.15]** ○ 1-3 times/month **[go to 7.15]** ○ 1-2 times/week ○ 3-5 times/week ○ Daily or almost every day
7.13	**If you exercise every week, what is your main type of exercise?** ○ Taichi/Qigong ○ Jogging/aerobic exercise ○ Ball games (e.g., basketball, table tennis) ○ Walking ○ Swimming ○ Other (e.g., Mountain climbing)
7.14	**During the past one-month, about how many hours per week did you spend doing such exercise in your leisure time?** _____ hours/weeks
7.15	**In a typical week during the past month, how often did you sweat or have a much faster heartbeat than normal because of heavy physical exertion/exercise?** ○ Never or almost never**[go to 7.15]** ○ < 1 times/week**[go to 7.15]** ○ 1-2 times/week ○ 3-5 times/week ○ Daily or almost every day
7.16	**About how many hours per week did you do such activities?** ____ hours/weeks
7.17	**About how many hours per week did you do housework?** ____ hours/weeks
7.18	**About how many hours per week did you watch TV or read?** ____ hours/weeks
7.19	**During the past month, has your weight changed significantly?**

	○ About the same as before ○ Yes, I have gained at least 5 Jin ○ Yes, I have lost at least 5 Jin					
7.20	**Have you tried to reduce your weight by diet or medication in the past month** ○ Yes ○ No					
7.21	**How much did you weigh when you were 25?** _____ Jin ○ Unknown					
8. Dietary						
8.1	**During the past month, how often did you consume the following foods?**					
	Food	**Daily**	**4-6 days/ week**	**1-3 days/ week**	**1-3 days/ month**	**None or little**
a)	Rice: including rice, rice porridge and rice noodles	○	○	○	○	○
b)	Wheat foods: foods containing wheat flour, such as noodles, steamed buns, breads, and pies	○	○	○	○	○
c)	Grains: all other food crops except wheat and rice, including millet, maize, sorghum	○	○	○	○	○
d)	Meat and meat products	○	○	○	○	○
e)	Poultry and poultry products	○	○	○	○	○
f)	Seafood and seafood products: including freshwater fish, shrimp, crab, and saltwater fish, shrimp, crab, and a variety of shellfish (fresh, frozen or processed)	○	○	○	○	○
g)	Eggs: fresh eggs or egg products (such as preserved eggs, salted eggs)	○	○	○	○	○
h)	Fresh vegetables	○	○	○	○	○
i)	Pickles, sauerkraut, preserved vegetables, pickled vegetables	○	○	○	○	○
j)	Fresh fruit	○	○	○	○	○
k)	Soy foods: various types of soy products (including tofu) and beverages (including soy	○	○	○	○	○

	milk) with soybean as a main raw material					
l)	Milk and dairy products: milk, goat's milk, yogurt, cheese, milk powder and pure dairy products	○	○	○	○	○
9. Health-related quality of life (EQ-5D)						
	The following questions ask about your current health status. In each of the following categories, please indicate which statement best describes your own health status today.					
9.1	**Mobility** ○ I have no problems walking around. ○ I have some problems walking around. ○ I am confined to bed.					
9.2	**Self-care** ○ I have no problems with self-care. ○ I have some problems washing or dressing myself. ○ I am unable to wash or dress myself.					
9.3	**Usual activities (e.g., work, study, housework, family or leisure activities)** ○ I have no problems performing my usual activities. ○ I have some problems performing my usual activities. ○ I am unable to perform my usual activities.					
9.4	**Pain/discomfort** ○ I have no pain or discomfort. ○ I have moderate pain or discomfort. ○ I have extreme pain or discomfort.					
9.5	**Anxiety/depression** ○ I am not anxious or depressed. ○ I am moderately anxious or depressed. ○ I am extremely anxious or depressed.					
9.6	Please **score** how good or poor your own health was the week before this admission. The best health status is 100 and the worst is 0. Overall, how would you score your own health today, between 0 and 100? **Enter value between 0 and 100**: _____ ○ Unknown					

Appendix 11 Table of predefined ranges for measurement variables

Variables	Predefined ranges
SBP	80-180 mmHg
DBP	50-100 mmHg
Height	140-195 cm
Weight	35-100 cm
TC	2.59-10.36 mmol/L
TG	0.57-5.65 mmol/L
HDL	0.39-2.59mmol/L
Age	40-75

SBP: systolic blood pressure; DBP: diastolic blood pressure; TC: total cholesterol; TG: triglyceride; HDL: high-density lipoprotein cholesterol.

Appendix 12 Date management and security protocol

This document describes the data management and security protocols for the project.

Data Collection

To ensure rigorous health data collection and management, the National Center for Cardiovascular Disease (NCCD) developed an off-line electronic data collection (EDC) system and a web-based project management platform. At each local screening center, trained local workers directly entered results from the physical measurements into the EDC system. In each province, the partner hospital is expected to verify the quality and validity of the data collected from its local screening centers within the province. After verification, all data collected in the EDC system is transferred to a central computer with Internet access using an encrypted U disk. Once transferred to the central computer, the data is then encrypted and confidentially stored at the NCCD.

Data Verification

Data managers from the NCCD and partner hospitals monitor project progress and data quality using a web-based project management platform developed for the project. This platform provides management support for the hospitals, staff members, equipment, sampling materials and funds used in the pilot. Through this platform, data managers from the NCCD can also monitor project progress and data collection in each province. All data collected at each screening center should be entered into the EDC system and transferred to the NCCD on daily basis. Data managers from partner hospitals verify that the data being entered is complete and meets predefined data ranges and formats. Once a potential error is found, data managers from partner hospitals immediately review the relevant records and correct invalidate data entries.

Data Sharing

The Center for Disease Control and Prevention and the NCCD have permission to use the data collected in this project. The Health and Family Planning Commissions of each participating province only has access to the data collected with its own province. The partner hospitals and participating hospitals must obtain approval from a province before using that province's data.

Data Security

All data, including health assessments results and questionnaires, is treated as protected information and is securely stored in an encrypted and password-protected database at the NCCD. This database can be accessed by only a limited number of approved staff members. At the local sites, all medical staff members must use their own passwords to log into the off-line EDC system. The passwords are used not only to ensure data security, but also to create an audit trail of all data entered or changed. To make a change to the data, approved staff members must first enter their names and passwords as electronic signatures; all changes are, in this way, recorded. Protocols designed by NCCD to protect data are:

1. All data should be collected using the EDC system. Data, including health assessments results and questionnaires, is treated as protected information and is securely stored in an encrypted and password-protected database in NCCD. Therefore, data can be physically isolated from the external Internet.
2. The server used to store the data should be placed in a locked room. Passwords for entering the room should be changed quarterly. The room can be accessed by only a limited number of approved staff members. All project personnel and supervisors from the government or academic institutesmust obtain permission and their own password in order to access to the database.
3. The IT department at the NCCD is responsible for the maintenance of the server and the database, and backs up all files regularly.
4. All project staff members should be trained in data security and must sign a confidentiality agreement prior to participating in the project.
5. People who plan to use the data should first submit an application form to the data management department at the NCCD detailing their data usage goals. Only afterbeing approved by the data management department can people gain access to the database. All data usage is monitored by the data management department.
6. Data containing personal information must be encrypted when transferring by e-mail or wide area network (WAN).
7. All project staff membersare prohibited from divulging any participant information. Dissemination of results should be devoid of any participant's personal information. Only the unique project ID number, which is assigned to each participant, is used to identify participants during the data collection and analysis phases.